DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 990 filers reported holding DANAHER CORPORATION in Q3 2015. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,544,341,233 | +5.2% | 6,224,672 | +1.8% | 0.78% | +12.5% |
| Q2 2023 | $1,468,091,280 | -5.6% | 6,117,048 | -0.8% | 0.70% | -10.5% |
| Q1 2023 | $1,554,747,063 | -6.9% | 6,168,652 | -2.0% | 0.78% | -10.1% |
| Q4 2022 | $1,670,111,332 | +4.7% | 6,292,334 | +1.9% | 0.87% | -0.1% |
| Q3 2022 | $1,595,511,000 | +2.7% | 6,177,207 | +0.8% | 0.87% | +12.7% |
| Q2 2022 | $1,554,077,000 | -10.5% | 6,130,002 | +3.5% | 0.77% | +11.1% |
| Q1 2022 | $1,737,210,000 | -4.3% | 5,922,241 | +7.3% | 0.69% | +6.0% |
| Q4 2021 | $1,815,817,000 | +13.5% | 5,519,014 | +5.0% | 0.66% | +8.8% |
| Q3 2021 | $1,600,024,000 | +14.4% | 5,255,764 | +0.8% | 0.60% | +12.7% |
| Q2 2021 | $1,398,896,000 | +26.7% | 5,212,841 | +6.3% | 0.53% | +18.9% |
| Q1 2021 | $1,104,086,000 | +4.0% | 4,905,124 | +2.7% | 0.45% | 0.0% |
| Q4 2020 | $1,061,242,000 | +5.6% | 4,777,268 | +2.4% | 0.45% | -7.6% |
| Q3 2020 | $1,004,519,000 | +20.4% | 4,665,013 | +9.3% | 0.49% | +13.0% |
| Q2 2020 | $834,493,000 | +54.5% | 4,266,275 | +9.4% | 0.43% | +19.4% |
| Q1 2020 | $539,994,000 | -4.0% | 3,901,396 | +6.4% | 0.36% | +21.6% |
| Q4 2019 | $562,749,000 | +7.5% | 3,666,597 | +1.1% | 0.30% | +4.2% |
| Q3 2019 | $523,661,000 | +6.8% | 3,625,709 | +5.7% | 0.28% | +8.8% |
| Q2 2019 | $490,302,000 | +16.6% | 3,430,609 | +7.7% | 0.26% | +16.0% |
| Q1 2019 | $420,540,000 | +26.4% | 3,185,428 | -1.3% | 0.22% | +11.9% |
| Q4 2018 | $332,681,000 | -4.8% | 3,226,158 | +0.4% | 0.20% | +15.5% |
| Q3 2018 | $349,284,000 | +14.8% | 3,214,472 | +4.2% | 0.17% | +11.5% |
| Q2 2018 | $304,351,000 | +9.0% | 3,084,209 | +8.2% | 0.16% | +9.9% |
| Q1 2018 | $279,220,000 | +10.7% | 2,851,517 | +5.0% | 0.14% | +17.4% |
| Q4 2017 | $252,120,000 | +7.9% | 2,716,225 | -0.3% | 0.12% | +5.2% |
| Q3 2017 | $233,617,000 | +3.8% | 2,723,432 | +2.1% | 0.12% | +2.7% |
| Q2 2017 | $225,123,000 | -3.7% | 2,667,650 | -2.4% | 0.11% | -5.9% |
| Q1 2017 | $233,743,000 | +10.0% | 2,732,884 | +0.1% | 0.12% | +8.2% |
| Q4 2016 | $212,463,000 | +13.2% | 2,729,502 | +14.0% | 0.11% | +12.2% |
| Q3 2016 | $187,756,000 | -20.6% | 2,395,137 | +2.3% | 0.10% | -22.8% |
| Q2 2016 | $236,404,000 | +4.3% | 2,340,619 | -2.1% | 0.13% | +5.8% |
| Q1 2016 | $226,727,000 | +4.6% | 2,390,117 | +2.4% | 0.12% | +9.1% |
| Q4 2015 | $216,841,000 | +8.7% | 2,334,642 | -0.2% | 0.11% | +12.2% |
| Q3 2015 | $199,403,000 | -1.7% | 2,340,132 | -1.3% | 0.10% | +6.5% |
| Q2 2015 | $202,893,000 | +2.0% | 2,370,530 | +1.2% | 0.09% | +2.2% |
| Q1 2015 | $198,917,000 | -5.5% | 2,342,955 | -4.6% | 0.09% | -6.2% |
| Q4 2014 | $210,560,000 | +4.1% | 2,456,659 | -7.7% | 0.10% | +4.3% |
| Q3 2014 | $202,190,000 | +0.0% | 2,661,090 | +3.6% | 0.09% | +3.4% |
| Q2 2014 | $202,148,000 | -14.6% | 2,567,600 | -18.7% | 0.09% | -20.5% |
| Q1 2014 | $236,783,000 | -0.3% | 3,157,120 | +2.6% | 0.11% | -3.4% |
| Q4 2013 | $237,551,000 | +4.8% | 3,077,077 | -5.9% | 0.12% | -4.1% |
| Q3 2013 | $226,726,000 | +5.2% | 3,270,731 | -3.9% | 0.12% | -1.6% |
| Q2 2013 | $215,530,000 | – | 3,404,890 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |